Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 15 studies | 22% ± 7% | |
monocyte | 9 studies | 20% ± 4% | |
non-classical monocyte | 8 studies | 23% ± 8% | |
natural killer cell | 8 studies | 18% ± 3% | |
macrophage | 7 studies | 23% ± 8% | |
ciliated cell | 6 studies | 21% ± 5% | |
classical monocyte | 5 studies | 24% ± 8% | |
CD8-positive, alpha-beta T cell | 5 studies | 19% ± 2% | |
regulatory T cell | 5 studies | 23% ± 11% | |
epithelial cell | 4 studies | 29% ± 11% | |
club cell | 4 studies | 18% ± 3% | |
dendritic cell | 4 studies | 25% ± 12% | |
microglial cell | 4 studies | 28% ± 7% | |
respiratory goblet cell | 3 studies | 21% ± 5% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 16% ± 1% | |
mature NK T cell | 3 studies | 19% ± 1% | |
glomerular endothelial cell | 3 studies | 17% ± 1% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 19% ± 1% | |
fibroblast | 3 studies | 24% ± 5% | |
capillary endothelial cell | 3 studies | 19% ± 2% | |
endothelial cell of artery | 3 studies | 19% ± 3% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 20% ± 4% | |
abnormal cell | 3 studies | 20% ± 1% | |
alveolar macrophage | 3 studies | 22% ± 6% | |
astrocyte | 3 studies | 24% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 5329.32 | 578 / 578 | 100% | 39.78 | 1150 / 1155 |
esophagus | 100% | 2975.74 | 1445 / 1445 | 99% | 43.39 | 182 / 183 |
breast | 100% | 3059.30 | 459 / 459 | 98% | 49.44 | 1101 / 1118 |
ovary | 100% | 2030.66 | 180 / 180 | 98% | 35.57 | 422 / 430 |
prostate | 100% | 3068.25 | 245 / 245 | 98% | 27.89 | 492 / 502 |
stomach | 100% | 2178.60 | 358 / 359 | 98% | 29.04 | 279 / 286 |
thymus | 100% | 2936.10 | 653 / 653 | 97% | 27.56 | 586 / 605 |
intestine | 100% | 3325.27 | 966 / 966 | 97% | 26.41 | 509 / 527 |
uterus | 100% | 3232.10 | 170 / 170 | 96% | 44.79 | 440 / 459 |
liver | 100% | 4444.66 | 226 / 226 | 96% | 22.90 | 389 / 406 |
kidney | 100% | 2691.99 | 89 / 89 | 95% | 22.26 | 857 / 901 |
pancreas | 98% | 1872.98 | 322 / 328 | 96% | 32.54 | 171 / 178 |
bladder | 100% | 2250.00 | 21 / 21 | 92% | 28.98 | 463 / 504 |
skin | 99% | 1691.69 | 1787 / 1809 | 90% | 29.23 | 426 / 472 |
adrenal gland | 100% | 4103.05 | 258 / 258 | 80% | 13.87 | 185 / 230 |
brain | 77% | 917.05 | 2041 / 2642 | 87% | 20.98 | 616 / 705 |
adipose | 100% | 3127.12 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 6458.85 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 56.15 | 45 / 45 |
blood vessel | 100% | 2007.79 | 1331 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 6237.81 | 921 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 1467.74 | 853 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 1168.56 | 760 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 26.97 | 26 / 29 |
eye | 0% | 0 | 0 / 0 | 24% | 3.71 | 19 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042531 | Biological process | positive regulation of tyrosine phosphorylation of STAT protein |
GO_0034356 | Biological process | NAD biosynthesis via nicotinamide riboside salvage pathway |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0045087 | Biological process | innate immune response |
GO_0006302 | Biological process | double-strand break repair |
GO_0060335 | Biological process | positive regulation of type II interferon-mediated signaling pathway |
GO_0051607 | Biological process | defense response to virus |
GO_0010608 | Biological process | post-transcriptional regulation of gene expression |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043086 | Biological process | negative regulation of catalytic activity |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0070212 | Biological process | protein poly-ADP-ribosylation |
GO_0019082 | Biological process | viral protein processing |
GO_0035563 | Biological process | positive regulation of chromatin binding |
GO_0060330 | Biological process | regulation of response to type II interferon |
GO_0002230 | Biological process | positive regulation of defense response to virus by host |
GO_0016477 | Biological process | cell migration |
GO_1900182 | Biological process | positive regulation of protein localization to nucleus |
GO_0000077 | Biological process | DNA damage checkpoint signaling |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090734 | Cellular component | site of DNA damage |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0016779 | Molecular function | nucleotidyltransferase activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0003950 | Molecular function | NAD+ ADP-ribosyltransferase activity |
GO_0042393 | Molecular function | histone binding |
GO_0097677 | Molecular function | STAT family protein binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0070403 | Molecular function | NAD+ binding |
GO_0072570 | Molecular function | ADP-D-ribose binding |
GO_0140802 | Molecular function | NAD+-protein-C-terminal glycine ADP-ribosyltransferase activity |
GO_0044389 | Molecular function | ubiquitin-like protein ligase binding |
GO_1990404 | Molecular function | NAD+-protein ADP-ribosyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PARP9 |
Protein name | Poly(ADP-ribose) polymerase family member 9 Protein mono-ADP-ribosyltransferase PARP9 (EC 2.4.2.-) (ADP-ribosyltransferase diphtheria toxin-like 9) (ARTD9) (B aggressive lymphoma protein) (Poly [ADP-ribose] polymerase 9) (PARP-9) Poly (ADP-ribose) polymerase family, member 9, isoform CRA_b (Poly(ADP-ribose) polymerase family member 9) |
Synonyms | BAL1 hCG_17211 BAL |
Description | FUNCTION: ADP-ribosyltransferase which, in association with E3 ligase DTX3L, plays a role in DNA damage repair and in immune responses including interferon-mediated antiviral defenses . Within the complex, enhances DTX3L E3 ligase activity which is further enhanced by PARP9 binding to poly(ADP-ribose) . In association with DTX3L and in presence of E1 and E2 enzymes, mediates NAD(+)-dependent mono-ADP-ribosylation of ubiquitin which prevents ubiquitin conjugation to substrates such as histones . During DNA repair, PARP1 recruits PARP9/BAL1-DTX3L complex to DNA damage sites via PARP9 binding to ribosylated PARP1 . Subsequent PARP1-dependent PARP9/BAL1-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites . In response to DNA damage, PARP9-DTX3L complex is required for efficient non-homologous end joining (NHEJ); the complex function is negatively modulated by PARP9 activity . Dispensable for B-cell receptor (BCR) assembly through V(D)J recombination and class switch recombination (CSR) (By similarity). In macrophages, positively regulates pro-inflammatory cytokines production in response to IFNG stimulation by suppressing PARP14-mediated STAT1 ADP-ribosylation and thus promoting STAT1 phosphorylation . Also suppresses PARP14-mediated STAT6 ADP-ribosylation . . |
Accessions | ENST00000466126.1 G5E9U8 Q8IXQ6 ENST00000360356.6 [Q8IXQ6-1] C9K0E5 ENST00000492382.5 ENST00000462315.5 [Q8IXQ6-3] ENST00000471785.5 [Q8IXQ6-2] ENST00000682323.1 [Q8IXQ6-2] ENST00000477522.6 [Q8IXQ6-2] |